Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK Cervarix Setback: FDA Questions On HPV Vaccine Bode Well For Merck

Executive Summary

The launch of GlaxoSmithKline human papilloma virus vaccine Cervarix will be further delayed behind Merck's competing Gardasil vaccine after FDA issued a "complete response" letter related to the BLA Dec. 17

You may also be interested in...



Novartis Hopes To Avoid Long FDA Delay For MF59 Adjuvant in Flu Vaccine

Novartis is trying to convince FDA that its squalene vaccine adjuvant MF59 is a non-threatening vaccine component that does not deserve to get caught in a long regulatory review of new vaccine technologies

Novartis Hopes To Avoid Long FDA Delay For MF59 Adjuvant in Flu Vaccine

Novartis is trying to convince FDA that its squalene vaccine adjuvant MF59 is a non-threatening vaccine component that does not deserve to get caught in a long regulatory review of new vaccine technologies

GSK Will Answer FDA “Complete Response” Letter For Cervarix In Q2

GlaxoSmithKline will answer FDA's "complete response" letter for its Cervarix BLA in the second quarter, but the firm expects the product will require advisory committee review for final approval, CEO JP Garnier said during GSK's year-end earnings call

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS049153

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel